

Fab 13.37
07C10
05E02
05H01
MOI =4
% Dead cells
0
20
40
60
80
PA103
medium
10^{-12} 10^{-11} 10^{-10} 10^{-9} 10^{-8} 10^{-7} 10^{-6} 10^{-5} 10^{-4}
[competitor], M

Figure 1A



Fab 13.37
01E11
02B02
02G09
02B10
03B11
03E10
MOI =4
% Dead cells
0
20
40
60
80
PA103
medium
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5 10-4
[competitor], M

Figure 1B



% Dead cells
60
40
20
0
PA103
medium
MOI =1.5
Fab 13.37
13F07
12B02
04G10
04C03
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5 10-4
[competitor] M

Figure 1C



Fab 13.37
06B05
10C05
11B09
14B10
14E10
07E09
MOI = 3
% Dead cells
60
40
20
0
PA103
medium
10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5 10-4
[competitor], M

Figure 1D



Fab 13.37
256
257
258
259
261
269
271
MOI = 12
% Dead cells
80
60
40
20
PA103
medium
10-13 10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
[competitor] M

Figure 2A




Fab 13.37
277
283
285
308
275
319
335
MOI = 12
% Dead cells
80
60
40
20
PA103
medium
10-13 10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
[competitor] M

Figure 2B

Figure 3


PcrV(1-294)
PcrV(144-257)
LcrV(1-322)
Chimera 1
Chimera 2
Chimera 3
Chimera 4
Chimera 5
Chimera 6
Chimera 7
1
50
100
150
200
250
294
144
257
1
50
100
150
200
250
300
322
1
26
47
57
91
86
112
106
125
127
147
156
177
178
199
178
195
200
216
194
211
215
240
209
249
238
278



Buffer
Irrelevant Nanobody
A-376 10µg/mouse
A-339 10µg/mouse
A-360 10µg/mouse
Percent survival
100
75
50
25
0
0
28
38 43
58
68
96
time (hours)

Figure 4A






Buffer
Fab13.37 0,05µg/mou
A-376 0,028 µg/mou
A-339 0,028 µg/mous
A-360 0,028 µg/mous
Percent survival
100
80
60
40
20
0
0
43
48
53
72
101
125
time (hours)

Figure 4B


MPO in Lung SN (OD=460nm)
0.20
0.15
0.10
0.05
0.00
*p value<0.05 vs Buffer
*
Non infected
Buffer
Irrelevant Nb (0,028µg/mouse)
Tobramycin (10mg/Kg)
A-376 (0,028µg/mouse)
A-339 (0,028 µg/mouse)
A-360 (0,028 µg/mouse)
Fab 13.37 (0,05µg/mouse)


lung CFU (log10)
8
6
4
2
0
***
n.s.
*p value<0.05 vs Buffer
***
**
***
**
**
Non infected
Buffer
Irrelevant Nb (0,028µg/mouse)
Tobramycin (10mg/Kg)
A-376 (0,028µg/mouse)
A-339 (0,028 µg/mouse)
A-360 (0,028 µg/mouse)
Fab 13.37 (0,05µg/mouse)


Lung weight (% of total weight)
2.0
1.5
1.0
0.5
0.0
*p value<0.05 vs Buffer
***
***
***
***
***
***
Non infected
Buffer
Irrelevant Nb (0,028µg/mouse)
Tobramycin (10mg/Kg)
A-376 (0,028µg/mouse)
A-339 (0,028 µg/mouse)
A-360 (0,028 µg/mouse)
Fab 13.37 (0,05µg/mouse)



Buffer
A-376 0.028µg/mouse
A-339 0.028µg/mouse
A-360 0.028µg/mouse
Fab 13.37 0.05µg/mouse
Weight loss (% of initial BW)
105
100
95
90
85
80
0
1
2
3
4
5
Time (Days)

Figure 6



OD 500 Nebulisation experiment
reference samples (before nebulisation)
nebulised samples (day 1)
nebulised samples (day2)
0.1
0.08
0.06
0.04
0.02
0
Reference Nanobody
A009500339 + 0.01% tween 80
A009500360 + 0.01% tween 80
A009500354 + 0.01% tween 80
A009500376 + 0.01% tween 80
Reference Nanobody
A009500339
A009500360
A2009500354
A009500376
Reference Nanobody

Figure 7